Preclinical Research Supporting a p53-Therapeutics, Inc. Strategy to Overcome Cisplatin Resistance in Head and Neck Cancer October 16, 20260CommentsRead More
p53-Therapeutics is a founding tenant of Ocean State Labs powered by Portal innovations in Providence, Rhode Island July 13, 20260CommentsRead More
RI Life Science Hub invests $4.5M in biotech companies. Where it’s going. July 13, 20260CommentsRead More
R.I.’s first life science incubator to open in early 2026, with five inaugural companies July 13, 20260CommentsRead More
p53-Therapeutics, Inc. Announces New additions to the Executive Management Team May 7, 20260CommentsRead More
Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics September 18, 20240CommentsRead More
Dr. El-Deiry co-chairs the 15th International p53 Workshop in Philadelpha, Pennsylvania October 8-10, 2010 August 23, 20240CommentsRead MoreRead More
Dr. El-Deiry chairs AACR special conference on Cell Death Mechanisms and Cancer Therapy February 1-4, 2010 in San Diego, California August 23, 20240CommentsRead MoreRead More
Zhang, S., Zhou, L., Zhang, L., Pinho-Schwermann, M., Carneiro, B., Sedivy, J., and El-Deiry, W.S. Small molecule NSC59984 synergizes with PARP inhibitors in BRCA1 wild type ovarian cancer. 115th Annual AACR meeting, April 5-10, 2024, San Diego, CA. August 23, 20240CommentsRead More
